GlobeNewswire Press

  1. Hyperion Therapeutics' RAVICTI™ (Glycerol Phenylbutyrate) Liquid Receives FDA Approval For Treatment Of Urea Cycle Disorders 2/1/2013

    Hyperion Therapeutics, Inc. (Nasdaq: HPTX) today announced that the U.S. Food and Drug Administration (FDA) has approved RAVICTI for the treatment of Urea Cycle Disorders (UCD) in patients two years of age and older. The drug is expected to be commercially available by the end of April 2013. 

  2. Biodel Reports Positive Top-Line Results From Clinical Study Of Ultra-Rapid-Acting Insulin Analog Candidates 1/24/2013

    Biodel Inc. (Nasdaq:BIOD) today announced positive top-line results from a Phase 1 clinical trial of two ultra-rapid-acting insulin analog-based formulations, BIOD-238 and BIOD-250, conducted to evaluate the pharmacokinetic and injection site toleration profiles relative to Humalog®, a rapid-acting insulin analog.

  3. BARDA Continues Novavax' Influenza Vaccine Programs Following In-Process Review 1/24/2013

    Novavax, Inc. (Nasdaq:NVAX) today announced that the U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA) has completed an In-Process Review (IPR) of Novavax' contract covering the company's recombinant virus-like particle (VLP) vaccine candidates for pandemic and seasonal influenza.

  4. Intellipharmaceutics Closes US$1.5M Convertible Debenture Financing 1/10/2013

    Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has closed its previously-announced private placement financing (the "Financing") of US$1.5 million aggregate principal amount of unsecured convertible debentures (the "Debentures"), which will mature January 1, 2015.

  5. Tranzyme Pharma Announces Top-Line Results Of TZP-102 Phase 2b Trial 11/15/2012

    Tranzyme Pharma (Nasdaq:TZYM), today announced top-line results of the preliminary analysis of the first of two Phase 2b trials assessing the safety and efficacy of its oral ghrelin agonist, TZP-102 in diabetic patients with gastroparesis.

  6. Theravance And Alfa Wassermann Enter Into Agreement To Develop And Commercialize Velusetrag For Gastroparesis 10/2/2012

    Theravance, Inc. (Nasdaq:THRX) and Alfa Wassermann S.p.A. announced today that they have entered into an exclusive development and commercialization agreement in certain countries for velusetrag, Theravance's investigational 5-HT4 agonist in development for gastrointestinal motility disorders.

  7. VIVUS Reports Second Quarter And First Six Months 2012 Financial Results 8/7/2012

    VIVUS, Inc. (Nasdaq:VVUS), a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today reported its financial results for the second quarter and six months ended June 30, 2012.

  8. Idenix Pharmaceuticals Announces Restructuring Of Development And Commercialization Collaboration With Novartis Pharma AG 7/31/2012

    denix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that Idenix and Novartis Pharma AG (Novartis) entered into a termination and revised relationship agreement that restructures the development and commercialization collaboration that was established in May 2003. Idenix will host a conference call this morning at 8:00 a.m ET to discuss this agreement.

  9. Amicus Therapeutics And GlaxoSmithKline Expand Fabry Disease Collaboration 7/17/2012

    Amicus Therapeutics (Nasdaq:FOLD) and Glaxo Group Limited (GSK) today announced an expansion of their collaboration to develop and commercialize the investigational pharmacological chaperone migalastat HCl for Fabry disease.

  10. Chelsea Therapeutics To Implement Corporate Reorganization 7/10/2012

    Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced that its Board of Directors plans to promptly implement a corporate reorganization that includes a reduction in force, executive changes and changes to the Company's Board of Directors, and has authorized a plan to explore and evaluate strategic options for the Company, all with the goal of optimizing long-term stockholder value.